The FDA has approved lisocabtagene maraleucel (Breyanzi, Bristol-Myers Squibb) for relapsed or refractory marginal zone lymphoma (MZL) in adults after at least two prior lines of systemic therapy.
In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy ...
Breyanzi is approved for relapsed or refractory marginal zone lymphoma after two prior systemic therapies, showing high response rates in clinical trials. The TRANSCEND FL-MZL Cohort trial ...
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...
The accelerating adoption of personalized medicine and targeted therapies is reshaping the ALCL treatment landscape. Advances in molecular diagnostics have improved subtype differentiation, enabling ...
Age-adjusted rate of developing BIA-ALCL 16 times higher for women with mutations versus without. HealthDay News — For women with breast cancer (BC), BRCA mutations are associated with increased risk ...
WEDNESDAY, June 25, 2025 (HealthDay News) -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results